{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:00:27Z","timestamp":1782450027529,"version":"3.54.5"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondazione Cariverona"},{"name":"Lega Italiana Fibrosi Cistica onlus"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Several reports have indicated that SARS-CoV-2 infection displays unexpected mild clinical manifestations in people with cystic fibrosis (pwCF), suggesting that CFTR expression and function may be involved in the SARS-CoV-2 life cycle. To evaluate the possible association of CFTR activity with SARS-CoV-2 replication, we tested the antiviral activity of two well-known CFTR inhibitors (IOWH-032 and PPQ-102) in wild type (WT)-CFTR bronchial cells. SARS-CoV-2 replication was inhibited by IOWH-032 treatment, with an IC50 of 4.52 \u03bcM, and by PPQ-102, with an IC50 of 15.92 \u03bcM. We confirmed this antiviral effect on primary cells (MucilAirTM wt-CFTR) using 10 \u03bcM IOWH-032. According to our results, CFTR inhibition can effectively tackle SARS-CoV-2 infection, suggesting that CFTR expression and function might play an important role in SARS-CoV-2 replication, revealing new perspectives on the mechanisms governing SARS-CoV-2 infection in both normal and CF individuals, as well as leading to potential novel treatments.<\/jats:p>","DOI":"10.3390\/cells12050776","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T03:03:48Z","timestamp":1677639828000},"page":"776","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1044-3109","authenticated-orcid":false,"given":"Anna","family":"Lagni","sequence":"first","affiliation":[{"name":"Microbiology Section, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5746-3810","authenticated-orcid":false,"given":"Virginia","family":"Lotti","sequence":"additional","affiliation":[{"name":"Microbiology Section, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-7533","authenticated-orcid":false,"given":"Erica","family":"Diani","sequence":"additional","affiliation":[{"name":"Microbiology Section, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rossini","sequence":"additional","affiliation":[{"name":"Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercole","family":"Concia","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2739-4014","authenticated-orcid":false,"given":"Claudio","family":"Sorio","sequence":"additional","affiliation":[{"name":"General Pathology Section, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gibellini","sequence":"additional","affiliation":[{"name":"Microbiology Section, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gendrot, M., Andreani, J., Boxberger, M., Jardot, P., Fonta, I., Le Bideau, M., Duflot, I., Mosnier, J., Rolland, C., and Bogreau, H. (2020). Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. Travel Med. Infect. Dis., 37.","DOI":"10.1016\/j.tmaid.2020.101873"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Holwerda, M., V\u2019kovski, P., Wider, M., Thiel, V., and Dijkman, R. (2020). Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. Microorganisms, 8.","DOI":"10.1101\/2020.05.17.100404"},{"key":"ref_7","first-page":"342","article-title":"Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients","volume":"76","author":"Gronich","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Agarwal, A., Appiah, J.A., Arabi, Y., Blumberg, L., Calfee, C.S., Cao, B., Cecconi, M., Cooke, G., Dunning, J., and Geduld, H. (2020). A living WHO guideline on drugs for COVID-19. BMJ, 370.","DOI":"10.1136\/bmj.m3379"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcf.2020.04.012","article-title":"A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis","volume":"19","author":"Cosgriff","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jcf.2020.10.003","article-title":"The global impact of SARS-CoV-2 in 181 people with cystic fibrosis","volume":"19","author":"McClenaghan","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lotti, V., Merigo, F., Lagni, A., Di Clemente, A., Ligozzi, M., Bernardi, P., Rossini, G., Concia, E., Plebani, R., and Romano, M. (2022). CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells. Cells, 11.","DOI":"10.3390\/cells11081347"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","article-title":"SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology","volume":"101","author":"Ogando","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.4155\/fmc.11.87","article-title":"Developing novel antisecretory drugs to treat infectious diarrhea","volume":"3","author":"Choy","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Erdem, R., Ambler, G., Al-Ibrahim, M., Fraczek, K., Dong, S.D., Gast, C., Mercer, L.D., Raine, M., Tennant, S.M., and Chen, W.H. (2021). A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009969"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1021\/jm9009873","article-title":"Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model","volume":"52","author":"Tradtrantip","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1085\/jgp.201210885","article-title":"Convective washout reduces the antidiarrheal efficacy of enterocyte surface\u2013targeted antisecretory drugs","volume":"141","author":"Jin","year":"2013","journal-title":"J. Gen. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Filkins, L.M., and O\u2019Toole, G.A. (2015). Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat. PLOS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005258"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jviromet.2012.08.008","article-title":"Detection of viral and bacterial respiratory pathogens in patients with cystic fibrosis","volume":"186","author":"Johal","year":"2012","journal-title":"J. Virol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jcf.2007.12.002","article-title":"The role of respiratory viruses in cystic fibrosis","volume":"7","author":"Wat","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Corvol, H., de Miranda, S., Lemonnier, L., Kemgang, A., Gaubert, M.R., Chiron, R., Dalphin, M.L., Durieu, I., Dubus, J.C., and Houdouin, V. (2020). First Wave of COVID-19 in French Patients with Cystic Fibrosis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113624"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mondejar-Lopez, P., Quintana-Gallego, E., Giron-Moreno, R.M., Cortell-Aznar, I., Ruiz de Valbuena-Maiz, M., Diab-Caceres, L., Prados-Sanchez, C., Alvarez-Fernandez, A., Garcia-Marcos, P.W., and Pe\u00f1alver-Mellado, C. (2020). Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey. Respir. Med., 170.","DOI":"10.1016\/j.rmed.2020.106062"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Charlton, F.W., Pearson, H.M., Hover, S., Lippiat, J.D., Fontana, J., Barr, J.N., and Mankouri, J. (2020). Ion Channels as Therapeutic Targets for Viral Infections: Further Discoveries and Future Perspectives. Viruses, 12.","DOI":"10.3390\/v12080844"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1152\/ajplung.00314.2012","article-title":"Influenza matrix protein 2 alters CFTR expression and function through its ion channel activity","volume":"304","author":"Londino","year":"2013","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1096\/fj.14-268755","article-title":"Influenza virus M2 targets cystic fibrosis transmembrane conductance regulator for lysosomal degradation during viral infection","volume":"29","author":"Londino","year":"2015","journal-title":"FASEB J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Panou, M.M., Antoni, M., Morgan, E.L., Loundras, E.A., Wasson, C.W., Welberry-Smith, M., Mankouri, J., and Macdonald, A. (2020). Glibenclamide inhibits BK polyomavirus infection in kidney cells through CFTR blockade. Antiviral Res., 178.","DOI":"10.1016\/j.antiviral.2020.104778"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2020-215171","article-title":"TMEM16A\/ANO1 calcium-activated chloride channel as a novel target for the treatment of human respiratory syncytial virus infection","volume":"76","author":"Pearson","year":"2021","journal-title":"Thorax"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","article-title":"Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia","volume":"594","author":"Braga","year":"2021","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cesar-Silva, D., Pereira-Dutra, F.S., Giannini, A.L.M., and de Almeida, C.J.G. (2022). The Endolysosomal System: The Acid Test for SARS-CoV-2. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094576"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Padmanabhan, P., Desikan, R., and Dixit, N.M. (2020). Targeting TMPRSS2 and Cathepsin B\/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput. Biol., 16.","DOI":"10.26434\/chemrxiv.12213125"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Antigny, F., Norez, C., Becq, F., and Vandebrouck, C. (2011). CFTR and Ca2+ signaling in cystic fibrosis. Front. Pharmacol., 2.","DOI":"10.3389\/fphar.2011.00067"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1712984","article-title":"Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity","volume":"253","author":"Anderson","year":"1991","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.cell.2020.10.004","article-title":"SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses","volume":"183","author":"Banerjee","year":"2020","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Li, J.Y., Liao, C.H., Wang, Q., Tan, Y.J., Luo, R., Qiu, Y., and Ge, X.Y. (2020). The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res., 286.","DOI":"10.1016\/j.virusres.2020.198074"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Randhawa, P.K., Scanlon, K., Rappaport, J., and Gupta, M.K. (2020). Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.611275"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/ncb2090","article-title":"Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition","volume":"12","author":"Luciani","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2013.00001","article-title":"Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect","volume":"4","author":"Villella","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.15252\/embj.201593564","article-title":"Phosphatidylinositol 3-phosphates\u2014At the interface between cell signalling and membrane traffic","volume":"35","author":"Marat","year":"2016","journal-title":"EMBO J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ncb1740","article-title":"Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking","volume":"10","author":"Liang","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Merigo, F., Lotti, V., Bernardi, P., Conti, A., Di Clemente, A., Ligozzi, M., Lagni, A., Sorio, C., Sbarbati, A., and Gibellini, D. (2022). Ultrastructural Characterization of Human Bronchial Epithelial Cells during SARS-CoV-2 Infection: Morphological Comparison of Wild-Type and CFTR-Modified Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179724"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.devcel.2021.10.006","article-title":"ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress","volume":"56","author":"Chen","year":"2021","journal-title":"Dev. Cell"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pizzato, M., Baraldi, C., Boscato Sopetto, G., Finozzi, D., Gentile, C., Gentile, M.D., Marconi, R., Paladino, D., Raoss, A., and Riedmiller, I. (2022). SARS-CoV-2 and the Host Cell: A Tale of Interactions. Front. Virol., 1.","DOI":"10.3389\/fviro.2021.815388"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhang, J., Kennedy, A., Xing, L., Bui, S., Reid, W., Joppich, J., Ahat, E., Rose, M., Tang, Q., and Tai, A.W. (2022). SARS-CoV-2 triggers Golgi fragmentation via down-regulation of GRASP55 to facilitate viral trafficking. bioRxiv.","DOI":"10.1101\/2022.03.04.483074"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.cell.2020.10.039","article-title":"\u03b2-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway","volume":"183","author":"Ghosh","year":"2020","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1172\/JCI73193","article-title":"Defective goblet cell exocytosis contributes to murine cystic fibrosis\u2013associated intestinal disease","volume":"125","author":"Liu","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/JOE-18-0570","article-title":"Defective exocytosis and processing of insulin in a cystic fibrosis mouse model","volume":"241","author":"Edlund","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Eymieux, S., Uzbekov, R., Rouill\u00e9, Y., Blanchard, E., Hourioux, C., Dubuisson, J., Belouzard, S., and Roingeard, P. (2021). Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress. Cells, 10.","DOI":"10.3390\/cells10082047"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sbarigia, C., Vardanyan, D., Buccini, L., Tacconi, S., and Dini, L. (2022). SARS-CoV-2 and extracellular vesicles: An intricate interplay in pathogenesis, diagnosis and treatment. Front. Nanotechnol., 4.","DOI":"10.3389\/fnano.2022.987034"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Nakase, I., Ueno, N., Matsuzawa, M., Noguchi, K., Hirano, M., Omura, M., Takenaka, T., Sugiyama, A., Bailey Kobayashi, N., and Hashimoto, T. (2021). Environmental pH stress influences cellular secretion and uptake of extracellular vesicles. FEBS Open Bio, 11.","DOI":"10.1002\/2211-5463.13107"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/5\/776\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:45Z","timestamp":1760121885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/5\/776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cells12050776"],"URL":"https:\/\/doi.org\/10.3390\/cells12050776","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}